JPS647050B2 - - Google Patents
Info
- Publication number
- JPS647050B2 JPS647050B2 JP54004177A JP417779A JPS647050B2 JP S647050 B2 JPS647050 B2 JP S647050B2 JP 54004177 A JP54004177 A JP 54004177A JP 417779 A JP417779 A JP 417779A JP S647050 B2 JPS647050 B2 JP S647050B2
- Authority
- JP
- Japan
- Prior art keywords
- gamma globulin
- sulfonated
- buffer
- fraction
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010074605 gamma-Globulins Proteins 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 26
- 239000000872 buffer Substances 0.000 claims description 19
- 150000002500 ions Chemical class 0.000 claims description 17
- 238000000746 purification Methods 0.000 claims description 10
- 150000001450 anions Chemical class 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 4
- 230000002391 anti-complement effect Effects 0.000 description 21
- 108010008730 anticomplement Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 239000008363 phosphate buffer Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 9
- 229920005654 Sephadex Polymers 0.000 description 7
- -1 Tetrathionic acid alkali salt Chemical class 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000006277 sulfonation reaction Methods 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 3
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- IBUIVNCCBFLEJL-UHFFFAOYSA-M sodium;phosphoric acid;chloride Chemical compound [Na+].[Cl-].OP(O)(O)=O IBUIVNCCBFLEJL-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HAEPBEMBOAIUPN-UHFFFAOYSA-L sodium tetrathionate Chemical compound O.O.[Na+].[Na+].[O-]S(=O)(=O)SSS([O-])(=O)=O HAEPBEMBOAIUPN-UHFFFAOYSA-L 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP417779A JPS5598117A (en) | 1979-01-17 | 1979-01-17 | Purification of gamma-globulin derivative |
| US06/098,789 US4302384A (en) | 1979-01-17 | 1979-11-30 | Purification of gammaglobulin derivative |
| SE7909897A SE435786B (sv) | 1979-01-17 | 1979-11-30 | Rening av gammaglobulinderivat |
| CA341,901A CA1128418A (en) | 1979-01-17 | 1979-12-13 | Purification of gammaglobulin derivative |
| NL7909110A NL7909110A (nl) | 1979-01-17 | 1979-12-18 | Zuivering van gamma-globuline-derivaat. |
| IT28295/79A IT1127308B (it) | 1979-01-17 | 1979-12-20 | Purificazione di un derivato della gammaglobulina |
| DE19803001187 DE3001187A1 (de) | 1979-01-17 | 1980-01-15 | Verfahren zur herstellung von gereinigtem s-sulfoniertem gamma -globulin |
| AT0019180A AT368887B (de) | 1979-01-17 | 1980-01-15 | Verfahren zur herstellung von gereinigtem s-sulfoniertem gammaglobulin |
| CH35280A CH643861A5 (de) | 1979-01-17 | 1980-01-16 | Verfahren zum reinigen eines gamma-globulinderivats. |
| FR8001010A FR2446839A1 (fr) | 1979-01-17 | 1980-01-17 | Procede de purification de la gamma-globuline s-sulfonee |
| GB8001629A GB2039490B (en) | 1979-01-17 | 1980-01-17 | Purification of s-sulfonated gammaglobulin onion-exchange resins |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP417779A JPS5598117A (en) | 1979-01-17 | 1979-01-17 | Purification of gamma-globulin derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5598117A JPS5598117A (en) | 1980-07-25 |
| JPS647050B2 true JPS647050B2 (US20030220297A1-20031127-C00009.png) | 1989-02-07 |
Family
ID=11577423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP417779A Granted JPS5598117A (en) | 1979-01-17 | 1979-01-17 | Purification of gamma-globulin derivative |
Country Status (11)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57103649A (en) * | 1980-12-18 | 1982-06-28 | Asahi Chemical Ind | Sterilized gamma-globulin fixing column |
| US4470925A (en) * | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
| US4479895A (en) * | 1982-05-05 | 1984-10-30 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
| US4590002A (en) * | 1984-12-10 | 1986-05-20 | Ortho Diagnostic Systems, Inc. | Methods for preparation of highly purified, gamma globulins free of hepatitis-B-virus infectivity |
| JPS63121408A (ja) * | 1986-11-11 | 1988-05-25 | 三菱電機株式会社 | 三相一括形ガス絶縁開閉装置 |
| US4806346A (en) * | 1986-12-16 | 1989-02-21 | American Home Products Corporation | Method for isolation of antigen specific immunoglobulin |
| TWI320788B (en) | 2005-05-25 | 2010-02-21 | Hoffmann La Roche | Method for the purification of antibodies |
| JPWO2009035055A1 (ja) * | 2007-09-14 | 2010-12-24 | 一般財団法人化学及血清療法研究所 | インスリン様成長因子−１（ｉｇｆ−１）産生促進剤 |
| TWI610937B (zh) * | 2011-08-26 | 2018-01-11 | 巴克斯歐塔公司 | 用於降低血漿來源免疫球蛋白組成物之血栓性栓塞可能性的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3869436A (en) * | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| DE2560155C2 (de) * | 1974-03-08 | 1984-04-26 | Teijin Ltd., Osaka | Humanimmunglobulin-Derivat |
| JPS5417721B2 (US20030220297A1-20031127-C00009.png) * | 1974-03-08 | 1979-07-02 | ||
| US4100149A (en) * | 1975-08-28 | 1978-07-11 | Rhone-Poulenc Industries | Method of separating proteins by ion exchange |
-
1979
- 1979-01-17 JP JP417779A patent/JPS5598117A/ja active Granted
- 1979-11-30 SE SE7909897A patent/SE435786B/sv not_active IP Right Cessation
- 1979-11-30 US US06/098,789 patent/US4302384A/en not_active Expired - Lifetime
- 1979-12-13 CA CA341,901A patent/CA1128418A/en not_active Expired
- 1979-12-18 NL NL7909110A patent/NL7909110A/nl not_active Application Discontinuation
- 1979-12-20 IT IT28295/79A patent/IT1127308B/it active
-
1980
- 1980-01-15 AT AT0019180A patent/AT368887B/de not_active IP Right Cessation
- 1980-01-15 DE DE19803001187 patent/DE3001187A1/de active Granted
- 1980-01-16 CH CH35280A patent/CH643861A5/de not_active IP Right Cessation
- 1980-01-17 FR FR8001010A patent/FR2446839A1/fr active Granted
- 1980-01-17 GB GB8001629A patent/GB2039490B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| SE7909897L (sv) | 1980-07-18 |
| SE435786B (sv) | 1984-10-22 |
| JPS5598117A (en) | 1980-07-25 |
| IT7928295A0 (it) | 1979-12-20 |
| FR2446839A1 (fr) | 1980-08-14 |
| IT1127308B (it) | 1986-05-21 |
| DE3001187A1 (de) | 1980-07-31 |
| US4302384A (en) | 1981-11-24 |
| GB2039490B (en) | 1983-02-16 |
| NL7909110A (nl) | 1980-07-21 |
| CA1128418A (en) | 1982-07-27 |
| ATA19180A (de) | 1982-04-15 |
| DE3001187C2 (US20030220297A1-20031127-C00009.png) | 1989-01-19 |
| AT368887B (de) | 1982-11-25 |
| CH643861A5 (de) | 1984-06-29 |
| FR2446839B1 (US20030220297A1-20031127-C00009.png) | 1983-05-20 |
| GB2039490A (en) | 1980-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5877152A (en) | Method for isolation of highly pure von Willebrand Factor | |
| JP4218980B2 (ja) | 治療用の免疫グロブリンｇ濃厚液および該濃厚液の製造方法 | |
| AU2001273907B2 (en) | A method of producing IgG | |
| Coan et al. | Preparation and Properties of Alpha1‐Proteinase Inhibitor Concentrate from Human Plasma | |
| JPH0676338B2 (ja) | 高イオン性濃度媒体中の血漿及び組換え蛋白処方物 | |
| JP2547556B2 (ja) | ｒ−グロブリンの液状製剤 | |
| AU2001273907A1 (en) | A method of producing IgG | |
| JPS6160049B2 (US20030220297A1-20031127-C00009.png) | ||
| JPS647050B2 (US20030220297A1-20031127-C00009.png) | ||
| JPS6160817B2 (US20030220297A1-20031127-C00009.png) | ||
| US6063909A (en) | Preparation of factor IX | |
| WO1998030230A1 (fr) | Compositions proteinees et procede de production | |
| EP0339919B1 (en) | Method for purifying antithrombin-III and antithrombin-III preparation containing said antithrombin-III | |
| JPH03218399A (ja) | 尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物 | |
| EP0449897B1 (en) | A pure factor i protein and a process for producing said protein | |
| CA2190454A1 (en) | Process for producing thrombin | |
| JPH0899900A (ja) | 静注用免疫グロブリン製剤の製造方法 | |
| JP3806471B2 (ja) | 腫瘍転移増殖抑制効果を有するプラスミノーゲン断片および該断片の調製方法 | |
| JP4105249B2 (ja) | α２プラスミンインヒビターの製造方法 | |
| JP2729484B2 (ja) | アンチトロンビン−▲ｉｉｉ▼の精製方法 | |
| JPH01258700A (ja) | 血液凝固第４因子の精製方法 | |
| JP2618643B2 (ja) | 静注用免疫グロブリン製剤 | |
| JPH0625011A (ja) | ヒト尿性トリプシンインヒビター含有液状製剤及びその製造方法 | |
| JP2000290196A (ja) | 血圧低下抑制剤 | |
| JPH10147538A (ja) | 医療用アンチトロンビン−ｉｉｉの製造法 |
